Arvinas Stock News

Parametric Portfolio Associates LLC decreased its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 33.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,764 shares of the companys stock after selling 15,456 shares during the period. Parametric Portfolio Associates []

– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium –

Wells Fargo & Company MN lifted its position in Arvinas, Inc. (NASDAQ:ARVN) by 0.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 59,205 shares of the companys stock after buying an additional 500 shares during the period. Wells Fargo & Company []

Stock analysts at Cowen started coverage on shares of Arvinas (NASDAQ:ARVN) in a note issued to investors on Monday, Analyst Ratings Network reports. The brokerage set an outperform rating on the stock. A number of other research firms also recently issued reports on ARVN. Oppenheimer upgraded shares of Arvinas from a market perform rating to []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Arvinas, Inc. (NASDAQ:ARVN) has received an average rating of Buy from the nineteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings []

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -4.84% to the previous days close as strong demand from buyers drove the stock to $78.25. Actively observing the price movement in the last trading, the stock closed the session at $82.23, falling within a range of $77.68 and Analysts Predict A Surge In Arvinas Inc. (NASDAQ: ARVN)? Read More »

Prudential Financial Inc. grew its position in Arvinas, Inc. (NASDAQ:ARVN) by 2.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,733 shares of the companys stock after purchasing an additional 520 shares during the quarter. Prudential Financial Inc.s holdings in Arvinas were []

Arvinas Inc. (NASDAQ:ARVN) price on Friday, November 19, rose 4.95% above its previous days close as an upside momentum from buyers pushed the stocks value to $83.04. A look at the stocks price movement, the close in the last trading session was $79.12, moving within a range at $79.34 and $84.06. The beta value (5-Year Arvinas Inc. (NASDAQ:ARVN) Shares In 2021: Bullish Prospects Read More »

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArgeting Chimera (PROTAC ® ) protein degrader, will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021. ARV-471 is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 20,000 shares of the companys stock in a transaction dated Monday, November 15th. The stock was sold at an average price of $84.04, for a total transaction of $1,680,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. []

Arvinas was founded by Dr. Craig Crews, the pioneer in the field of targeted protein degradation.

LPL Financial LLC purchased a new position in Arvinas, Inc. (NASDAQ:ARVN) during the second quarter, Holdings Channel reports. The fund purchased 4,205 shares of the company’s stock, valued at approximately $324,000. Other hedge funds have also added to or reduced their stakes in the company. Rockefeller Capital Management L.P. grew its holdings in shares of […]